Related Experiment Video
Updated: Mar 19, 2026
Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors
Published on: October 17, 2025
Eradication of Acute Myeloid Leukemia with FLT3 Ligand-Targeted miR-150 Nanoparticles
Xi Jiang1, Jason Bugno2, Chao Hu3
1Department of Cancer Biology, University of Cincinnati, Cincinnati, Ohio. Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, Illinois. chen3jj@uc.edu jiangx4@uc.edu sphong@uic.edu.
Abstract:
Acute myeloid leukemia (AML) is a common and fatal form of hematopoietic malignancy. Overexpression and/or mutations of FLT3 have been shown to occur in the majority of cases of AML. Our analysis of a large-scale AML patient cohort (N = 562) indicates that FLT3 is particularly highly expressed in some subtypes of AML, such as AML with t(11q23)/MLL-rearrangements or FLT3-ITD. Such AML subtypes are known to be associated with unfavorable prognosis. To treat FLT3-overexpressing AML, we developed a novel targeted nanoparticle system: FLT3 ligand (FLT3L)-conjugated G7 poly(amidoamine) (PAMAM) nanosized dendriplex encapsulating miR-150, a pivotal tumor suppressor and negative regulator of FLT3 We show that the FLT3L-guided miR-150 nanoparticles selectively and efficiently target FLT3-overexpressing AML cells and significantly inhibit viability/growth and promote apoptosis of the AML cells. Our proof-of-concept animal model studies demonstrate that the FLT3L-guided miR-150 nanoparticles tend to concentrate in bone marrow, and significantly inhibit progression of FLT3-overexpressing AML in vivo, while exhibiting no obvious side effects on normal hematopoiesis. Collectively, we have developed a novel targeted therapeutic strategy, using FLT3L-guided miR-150-based nanoparticles, to treat FLT3-overexpressing AML with high efficacy and minimal side effects. Cancer Res; 76(15); 4470-80. ©2016 AACR.
Insights
Researchers developed FLT3 ligand-guided nanoparticles carrying miR-150 to target Acute Myeloid Leukemia (AML) cells. This novel therapy effectively inhibits AML growth and promotes apoptosis with minimal side effects in preclinical models.
Area of Science:
- Oncology
- Nanotechnology
- Molecular Biology
Background:
- Acute myeloid leukemia (AML) is a fatal blood cancer.
- FLT3 mutations/overexpression occur in most AML cases, correlating with poor prognosis.
- Targeting FLT3 is a promising therapeutic strategy for AML.
Purpose of the Study:
- To develop and evaluate a novel targeted nanoparticle system for FLT3-overexpressing AML.
- To investigate the efficacy of FLT3 ligand (FLT3L)-conjugated nanoparticles encapsulating miR-150 in AML treatment.
- To assess the safety and biodistribution of the nanoparticles in vivo.
Main Methods:
- Development of FLT3L-conjugated poly(amidoamine) (PAMAM) dendriplex nanoparticles encapsulating miR-150.
- In vitro studies to assess targeting, cell viability, growth inhibition, and apoptosis induction in AML cells.
- In vivo studies in animal models to evaluate nanoparticle biodistribution, anti-leukemic efficacy, and effects on hematopoiesis.
Main Results:
- FLT3L-guided nanoparticles selectively targeted and efficiently inhibited FLT3-overexpressing AML cells in vitro.
- Nanoparticles promoted apoptosis and significantly reduced viability/growth of AML cells.
- In vivo studies showed nanoparticles concentrated in bone marrow, inhibited AML progression, and had no obvious side effects on normal hematopoiesis.
Conclusions:
- FLT3L-guided miR-150 nanoparticles represent a novel, effective, and safe targeted therapeutic strategy for FLT3-overexpressing AML.
- This approach offers high efficacy with minimal adverse effects, showing promise for clinical translation.
- The study provides a proof-of-concept for nanoparticle-based drug delivery in treating specific AML subtypes.
